InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,257.35
(
0.26%
)
Post# of 252302
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119891
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biomaven0 post# 87691

Thursday, 12/17/2009 4:00:19 PM

Thursday, December 17, 2009 4:00:19 PM

Post# of 252302
PYMX MNTA:

I hadn't quite realized the growing dominance of Lovenox (seems to currently have about 80% of the LMWH market as best I can tell)…

It’s even more than that. According to SNY, Lovenox’s share of the US market for LMWH’s is about 95%; Fragmin and InnoHep have 1-2% each, and everything else is essentially round-off error.

Arixtra, which is not a LMWH, is also a non-factor in the market despite its being a fine drug.

In short, the heparin-based market boils down to two products: UFH and Lovenox.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up